Company Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 12:46:52 2024-05-17 pm EDT			5-day change	1st Jan Change
5.38 ^USD	-1.47%		-15.29%	+60.99%

May. 16	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating	MT
May. 07	HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating	MT

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Number of employees: 140

Managers	Title	Age	Since
Talat Imran CEO	Chief Executive Officer	43	21-05-31
Mir Imran FOU	Founder	67	21-04-05
Svai Sanford DFI	Director of Finance/CFO	54	21-04-05
Jacques Van Dam CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	21-04-05
Bella Vazquez HRO	Human Resources Officer	-	21-06-30
Eric Groen LAW	General Counsel	53	21-09-08
Kate McKinley PRN	Corporate Officer/Principal	47	23-05-23
Arvinder Dhalla PRN	Corporate Officer/Principal	-	21-06-30
J. Christopher Prue LAW	General Counsel	-	21-06-30

Members of the board	Title	Age	Since
Laureen DeBuono BRD	Director/Board Member	66	21-04-05
Jean-Luc Butel BRD	Director/Board Member	67	21-04-05
Dennis Ausiello BRD	Director/Board Member	78	21-04-05
Mir Imran FOU	Founder	67	21-04-05
Andrew Farquharson BRD	Director/Board Member	55	21-04-05
Talat Imran CEO	Chief Executive Officer	43	21-05-31
Maulik Nanavaty BRD	Director/Board Member	62	21-04-05
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	21-04-05
Lisa Rometty BRD	Director/Board Member	56	22-01-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	24,116,000	0	0	26.67 %
Stock B	1	26,303,871	13,446,618 ( 51.12 %)	0

Name	Equities	%	Valuation
South Cone Investments LP 46.13 %	12,131,554	46.13 %	77 M $
Vanguard Global Advisers LLC 2.606 %	685,303	2.606 %	4 M $
Pivotal Bioventure Partners Investment Advisor LLC 1.877 %	493,584	1.877 %	3 M $
Mir Imran 1.842 %	484,455	1.842 %	3 M $
United Services Automobile Association 1.830 %	481,300	1.830 %	3 M $
TEIJIN LIMITED 1.714 %	450,733	1.714 %	3 M $
ALPHABET INC. 1.705 %	448,492	1.705 %	3 M $
Talat Imran 0.6892 %	181,238	0.6892 %	1 M $
Eric Groen 0.6206 %	163,216	0.6206 %	1 M $
Mir Hashim 0.5643 %	148,415	0.5643 %	946 888 $

Name	Equities	%	Valuation
Mir Hashim -	374,119	-	2 M $
Andrew Farquharson -	242,421	-	2 M $
Maulik Nanavaty -	155,118	-	989 653 $
Svai Sanford -	142,350	-	908 193 $
Dennis Ausiello -	92,074	-	587 432 $
Talat Imran -	43,484	-	277 428 $

Name	Equities	%	Valuation
In-Cube, Inc. 76.57 %	22,411,124	76.57 %	143 M $
Andrew Farquharson 0.7972 %	233,333	0.7972 %	1 M $
Maulik Nanavaty 0.1807 %	52,878	0.1807 %	337 362 $
Mir Hashim 0.0876 %	25,649	0.0876 %	163 641 $

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue

95131, San Jose

http://www.ranitherapeutics.com

address Rani Therapeutics Holdings, Inc.(RANI)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.46 USD

Average target price

10.57 USD

Spread / Average Target

+93.62%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RANI THERAPEUTICS HOLDINGS, INC.	+67.47%	144M
VERTEX PHARMACEUTICALS INCORPORATED	+8.60%	114B
REGENERON PHARMACEUTICALS, INC.	+10.65%	104B
BIONTECH SE	-12.74%	22.41B
ARGENX SE	-0.67%	22.28B
GENMAB A/S	-5.80%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.13%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.46%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.38%	12.55B

Bio Therapeutic Drugs